Released Mar 2, 2015, after the close
10-K filed Mar 2, 2015, 61 days after period end · 0000320017-15-000013
Q4 2013 · 10-K
Revenue$5.28K$5.28K no prior Q4 2012 on file+28.1% vs Q3 2013
Net Income-$11.61K-$11.61K N/M vs Q4 2012N/M vs Q3 2013
EPS Diluted-$0.32-$0.32 N/M vs Q4 2012N/M vs Q3 2013
Operating Incomederived-$15,552,824—
Operating Cash Flowderived-$10,903,997N/M
Free Cash Flowderived-$11,635,431N/M
Margins · derived
Operating margin-294784.4%
Net margin-220.1%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2013 | Q4 2012 | Q4 2011dderived from reported figures | Q4 2010dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.28K | — | $2.75M | — |
| Net Income | -$11.61K | -$12.54K | -$15.51M | -$19.01M |
| EPS Diluted | -$0.32 | -$0.47 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR